Straits Times Index
3,219.60 +0.60 (+0.02%) Nikkei
27,322.41 -97.20 (-0.35%) Hang Seng
20,007.19 -42.45 (-0.21%) FTSE 100
7,499.60 -67.24 (-0.89%) BTC-USD
28,265.28 +838.85 (+3.06%) CMC Crypto 200
618.24 +20.78 (+3.48%)
Roche Holding AG (RHHVF)
- Zacks
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.
- Motley Fool
Is Roche a Buy Now?
Swiss healthcare company Roche Holding (OTC: RHHBY) doesn't trade on the NYSE or NASDAQ, so the company is sometimes overlooked considering its size, scope and consistent revenue growth. Roche, with its roughly 140,000 employees, has increased revenue by 36% over the past 10 years and annual earnings per share (EPS) by 27% in that period. There are two likely reasons for the decline of Roche's shares.
- Business Wire
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif., March 20, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi® (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data confirm increases in motor function were sustained at four years and the overall rate of adverse events continued to decrease over the 48-month period, reinforcing the long-term efficacy and safety of Evrysdi. P
